Evidence map›Paper›PMID 41499761›Full record

Trial reportBlood advances2026

MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.

Marie Ouellet, Angelo Rizzolo, Caroline Venne, Hanane Moussa, Karine Bilodeau, Luigina Mollica, Geneviève Chabot-Roy, Geneviève Huynh-Trudeau, Sylvie Lesage, Michaël Harnois and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Marie OuelletDepartment of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Canada.ORCID 0009-0007-1888-8190
Angelo RizzoloSegal Cancer Centre, Jewish General Hospital, Montreal, Canada.ORCID 0000-0002-2600-7361
Caroline VenneQuebec Kinesiologist Federation, Montreal, Canada.
Hanane MoussaQuebec CML-MPN Research Group, Montreal, Canada.
Karine BilodeauFaculty of Nursing, University of Montreal, Montreal, Canada.
Luigina MollicaDepartment of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Canada.
Geneviève Chabot-RoyMaisonneuve-Rosemont Hospital Research Centre, Montreal, Canada.
Geneviève Huynh-TrudeauDepartment of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Canada.
Sylvie LesageMaisonneuve-Rosemont Hospital Research Centre, Montreal, Canada.ORCID 0000-0002-0968-2795
Michaël HarnoisQuebec CML-MPN Research Group, Montreal, Canada.
Lambert BusqueDepartment of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Canada.ORCID 0000-0002-5375-3749
Shireen SirhanSegal Cancer Centre, Jewish General Hospital, Montreal, Canada.
Natasha SzuberDepartment of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Canada.ORCID 0000-0003-1499-6171

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractMyeloproliferative neoplasms (MPN) are associated with a high symptom burden and impaired quality of life (QoL), often unaided by available treatments. Physical activity has demonstrated benefits in other cancers; however, its potential has yet to be explored in MPN. This randomized controlled trial aimed to evaluate the feasibility, acceptability, and efficacy of a supervised exercise program for patients with MPN based on longitudinal assessment of symptom burden, QoL, and clinical/inflammatory markers (C-reactive protein, erythrocyte sedimentation rate, ferritin, lactate dehydrogenase [LDH], and serum cytokines). Patients with MPN (n = 55) were randomized 3:2 to a 12-week home-based exercise intervention (flexibility/resistance/aerobics) supervised by a kinesiologist vs waitlist control. Measures included patient-reported outcome questionnaires, peripheral blood sampling, and postintervention interviews with participants. Forty-seven patients completed the trial (FIT group, n = 26; control group, n = 21). Median age was 66 years (range, 27-86), and 60% were female. All feasibility benchmarks were met, with 88% of participants satisfied and 92% with intent to continue an exercise program on a regular basis. A significant reduction in LDH was observed in FIT patients compared with controls (-14.5 U/L vs +4.0 U/L; P = .03). Patients interviewed described positive effects of the intervention on symptoms and would unanimously recommend the program to others with MPN. In this pilot study, supervised exercise was feasible, acceptable, and showed potential benefits on inflammatory/disease markers.

Indexed as

ExerciseExercise TherapyMyeloproliferative DisordersAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPilot ProjectsQuality of LifeTreatment Outcome

Identifiers

PMID41499761
PMCPMC13049634

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.